SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

S. Daniluk; B.K. Skrumsager; P. Leszczynski

doi:10.1136/annrheumdis-2014-eular.3239

SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3239 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 684.3-685 ◽

Cited By ~ 1

Author(s):

S. Daniluk ◽

B.K. Skrumsager ◽

P. Leszczynski

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Multiple Dose ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Trial

Download Full-text

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

O1-02-06: ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96-WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.2341 ◽

2006 ◽

Vol 14 (7S_Part_4) ◽

pp. P218-P219

Author(s):

Hana Florian ◽

Kumar Budur ◽

Deli Wang ◽

Weining Z. Robieson ◽

Holly Soares ◽

...

Keyword(s):

Monoclonal Antibody ◽

Study Design ◽

Multiple Dose ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Baseline Characteristics ◽

Early Alzheimer’S Disease ◽

Disease Study

Download Full-text

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

Inflammatory Bowel Diseases ◽

10.1002/ibd.21038 ◽

2010 ◽

Vol 16 (2) ◽

pp. 233-242 ◽

Cited By ~ 137

Author(s):

Walter Reinisch ◽

Williem de Villiers ◽

László Bene ◽

László Simon ◽

István Rácz ◽

...

Keyword(s):

Multiple Dose ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Dose Study ◽

Dose Study

Download Full-text

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Download Full-text

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

Arthritis & Rheumatism ◽

10.1002/art.27524 ◽

2010 ◽

Vol 62 (8) ◽

pp. 2227-2238 ◽

Cited By ~ 69

Author(s):

Mikkel Østergaard ◽

Bo Baslund ◽

William Rigby ◽

Bernadette Rojkovich ◽

Christian Jorgensen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase I ◽

Inadequate Response ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Anti Cd20

Download Full-text

JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study

Journal of Hepatology ◽

10.1016/s0168-8278(20)30779-0 ◽

2020 ◽

Vol 73 ◽

pp. S133

Author(s):

Kuo-Chin Huang ◽

Ming-Yao Chen ◽

Chih-Lin Lin ◽

Sien-Sing Yang ◽

Chao-Wei Hsu ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Multiple Dose ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Double Blind Placebo ◽

Alcoholic Fatty Liver Disease

Download Full-text

A randomized, double-blind, placebo-controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.1780380812 ◽

1995 ◽

Vol 38 (8) ◽

pp. 1097-1106 ◽

Cited By ~ 99

Author(s):

Peter A. Van Der Lubbe ◽

Ben A. C. Dijkmans ◽

Hendrik M. Markusse ◽

Ulla Nässander ◽

Ferdinand C. Breedveld

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Early Rheumatoid Arthritis ◽

Antibody Therapy ◽

Controlled Study ◽

Monoclonal Antibody Therapy ◽

Double Blind ◽

Double Blind Placebo

Download Full-text